ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

3:00PM-3:15PM: Abstract Number: 2633

Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

3:00PM-3:15PM: Abstract Number: 2621

Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)

Abstracts: Osteoarthritis – Clinical (2621–2626)

3:00PM-3:15PM: Abstract Number: 2603

Evaluating the Feasibility, Acceptability, and Behavioral Impact of Brief Action Planning (BAP) Coaching for Physical Activity in Adults with Chronic Knee Symptoms: A Qualitative Study

Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

3:00PM-3:15PM: Abstract Number: 2609

Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study

Abstracts: Imaging of Rheumatic Diseases (2609–2614)

3:00PM-3:15PM: Abstract Number: 2627

Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study

Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)

3:00PM-3:15PM: Abstract Number: 2615

The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection

Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

3:15PM-3:30PM: Abstract Number: 2628

Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia

Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)

3:15PM-3:30PM: Abstract Number: 2604

Cross-Sectional Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The Johnston County Osteoarthritis Project

Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

3:15PM-3:30PM: Abstract Number: 2610

Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy

Abstracts: Imaging of Rheumatic Diseases (2609–2614)

3:15PM-3:30PM: Abstract Number: 2622

Oral Microbiome Dysbiosis and Oral-gut Microbial Network Disruption in Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study

Abstracts: Osteoarthritis – Clinical (2621–2626)

3:15PM-3:30PM: Abstract Number: 2616

Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis

Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

3:15PM-3:30PM: Abstract Number: 2634

Sex differences in medication discontinuation in axial spondyloarthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

3:30PM-3:45PM: Abstract Number: 2617

Design and Initial Results from a Cluster Randomized Trial of a Provider-Facing Immunization Dashboard to Improve Shingrix Vaccination in the Veterans Health Administration

Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

3:30PM-3:45PM: Abstract Number: 2635

Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

3:30PM-3:45PM: Abstract Number: 2623

Disease Activity is a Novel Imaging Biomarker Associated with Knee Pain: Data from the Osteoarthritis Initiative

Abstracts: Osteoarthritis – Clinical (2621–2626)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].